Login to Your Account

FDA Panel, Roche Trial Ahead

Amgen's Moves Gain Praise As Firm Faces 'Uncertainties'

By Randall Osborne

Friday, August 17, 2007
The bound-to-happen changes disclosed Wednesday by Amgen Inc. failed to shock Wall Street, and eyes now have turned to the firm's date with an FDA panel on erythropoietin stimulating agents (ESAs) and a court fight over patents with F. Hoffmann-La Roche Ltd. - even as hopes remain in some quarters that the feds might modify their reimbursement guidelines for anemia drugs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription